Bayer Presents Advancements in Radiology Pipeline and AI Innovations

Bayer (Leverkusen, Germany) continues to advance its comprehensive Radiology portfolio with progress in the development pipeline for an investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company is presenting new clinical data for gadoquatrane, Bayer’s investigative macrocyclic gadolinium-based compound currently in Phase III development, at the 2023 Radiological Society of North America (RSNA) Annual Meeting – taking place from November 26 to 30 in Chicago, USA. In addition, Bayer has announced four collaboration agreements, adding additional applications to its digital platform Calantic Digital Solutions. Bayer is also announcing the publication of a Bayer-funded health economic modeling analysis that evaluated cost-effectiveness of supplemental imaging for screening breast cancer in women with dense breasts. The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to accelerate innovation and address today’s industry challenges for the benefit of patients and their clinicians.

In more than 30 sessions, Bayer’s AI team composed jointly of experts from both Calantic Digital Solutions and Blackford Analysis, will be sharing their insights to help customers advance their AI strategy – by offering various tech talks, including “Spark Tank Sessions” where early-stage app companies can learn new ways to refine their value proposition and market their AI. Bayer is also hosting thought leadership panel discussions with topics like regulatory challenges in the field of AI in medical imaging, app selection, and leveraging clinical utility frameworks to assess ROI.

Image: Bayer is highlighting its innovations in fluid delivery and contrast media at RSNA 2023 (Photo courtesy of Bayer)

Building on technology from Blackford and adding additional workflow and analytics components, Bayer’s own platform Calantic Digital Solutions delivers access to applications for medical imaging, including those enabled by AI. Calantic SPARK, Bayer’s accelerator program for medical imaging app developers to further foster innovation in radiology AI, is showcasing Imagine Software and Scanslated. Bayer’s Calantic Spark is a targeted program to help radiology AI startups of all stages get to market faster by offering advice spanning medical, regulatory, reimbursement expertise, and market access. During RSNA, Bayer is also hosting an immersive tour of a radiology clinic of the future through the eyes of a patient.

Related Links:
Bayer